Cyfuse Biomedical KK

Cyfuse Biomedical KK R&D per Employee

The R&D Spending per Employee of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is 22.36 M JPY. In the previous year, R&D Spending per Employee was 17.88 M JPY — a change of 25.02% (higher).

R&D per Employee

22.36 MJPY

YoY

25.02%

Last updated:

R&D Spending per Employee of Cyfuse Biomedical KK is 2024 22.36 M JPY. R&D Spending per Employee of Cyfuse Biomedical KK was 2023 17.88 M JPY. It decreases by 25.02% higher compared to the previous year.

The Cyfuse Biomedical KK R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2020
11.55 M JPY
Jan 1, 2021
12.69 M JPY
Jan 1, 2022
14.46 M JPY
Jan 1, 2023
17.88 M JPY
Jan 1, 2024
22.36 M JPY
The Cyfuse Biomedical KK R&D per Employee history
YEARR&D per EmployeeYoY
22.36 MJPY+25.02%
17.88 MJPY+23.67%
14.46 MJPY+13.96%
12.69 MJPY+9.85%
11.55 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

R&D Spending per Employee of Cyfuse Biomedical KK is 22.36 M JPY in 2024.

R&D Spending per Employee of Cyfuse Biomedical KK changed from 17.88 M JPY to 22.36 M JPY, representing a 25.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Cyfuse Biomedical KK historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Cyfuse Biomedical KK

All Key Metrics — Cyfuse Biomedical KK